

## Release of Investor Presentations Represent Non-Deal Roadshows

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) would like to clarify, given shareholder queries and market speculation, that the ASX release on 5 April 2022, titled Investor Presentation and the release following this notice, titled 'Pac Partners Inaugural Healthcare Conference' are in regard of in-person investor presentations and should be considered a non-deal roadshow.

The release of the presentations onto the ASX platform is in line with ASX governance practices.

### Non-Deal Roadshow (Investor Presentations)

The Company confirms it:

- ✓ is not seeking to effect any transactions as a result of these presentations;
- ✓ is well capitalised, with cash at bank of \$10.8m as of 28 February 2022;
- ✓ anticipates receiving up to circa \$3.84m, as a result of (\$1.20) in-the-money options expiring on 31 August 2022;
- ✓ expects to receive a Research & Development tax refund circa in line with the \$2.4m received in 1H'FY22 by the end of the calendar year; and
- ✓ is targeting first revenues late CY'22.

- ENDS -

Authorised for release by the Board.

### For further information contact:

Glenn Gilbert  
CEO and Managing Director  
+61 3 8256 2880

### About Rhythm Biosciences

Rhythm Biosciences Ltd  
ACN 619 459 335  
ASX: RHY

[www.rhythmbio.com](http://www.rhythmbio.com)

Australian Registered Address  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

T +61 3 8256 2880  
E [info@rhythmbio.com](mailto:info@rhythmbio.com)

#### Directors

Otto Buttula  
Glenn Gilbert  
Trevor Lockett  
Rachel David  
Louis Panaccio  
Eduardo Vom

Executive Chairman  
Managing Director  
Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director

Rhythm Biosciences is focused on becoming a globally significant, transformative, predictive diagnostics company, specialising in cancer detection technology. The Company is currently developing ColoSTAT® - a simple, low-cost, blood test for global mass market detection of colorectal cancer.

Worldwide, colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

In an effort to reduce the global burden, many countries have implemented screening programs aimed at early detection. These programs are predominantly administered with a faecal immunochemical test (FIT) for the assessment of colorectal cancer risk, with a positive result referred for a colonoscopy. FIT only analyses the presence of blood in faeces, which can occur for several reasons other than cancer, therefore it is not designed as an accurate test for cancer. Many people simply don't take the test for fear of an unnecessary colonoscopy procedure, unpleasantness, difficulty, or for religious/cultural reasons. There is currently no appropriate blood test alternative.

Rhythm aims to transform the global mass-market for colorectal cancer detection with ColoSTAT® its simple, low-cost blood test that is fit for purpose, meaning that it is designed to actually detect colorectal cancer. Since listing on the ASX in 2017, the Company has run a successful multi-year research and development program that has delivered technical validation of the core biomarker technology, being reproducible and stable. The ColoSTAT® test-kit was manufactured in 2021 and delivered performance testing that outperforms the current market standard faecal immunochemical test (FIT) utilising Rhythm's proprietary algorithm. The Company is currently finalising its clinical trial for ColoSTAT®, and is progressing regulatory, manufacturing and scale up activities ahead of market entry in 2022.

ColoSTAT® is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT® has the potential to play a key role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Rhythm's initial targeted global addressable population is over 800 million people which are over 50 years of age. Almost 70%, or 550 million people, are not currently screened for colorectal cancer due to the limitations of the current faecal based testing regime. This "at risk" population is also expanding with the disease growing rapidly in much younger age groups. Early detection and intervention can lead to cure in over 90 per cent of new cases, therefore the need for effective screening and early intervention has the potential to save a significant number of lives. Rhythm estimates today's colorectal cancer screening market alone to be worth in excess of \$38 billion.



# PAC Partners Inaugural Healthcare Conference

6 April 2022 [ASX:RHY](#)

*A transformative and predictive  
cancer diagnostics technology company*

[rhythmbio.com](https://rhythmbio.com)

# Disclaimer



This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.



# Introduction



Rhythm's initial product, ColoSTAT® is a **simple, low-cost** blood test for the early detection of colorectal cancer for **global mass-market** screening.

IP protection **secured** in all major international jurisdictions.

Commenced **platform technology** program for multiple / pan cancer targets.

# ColoSTAT® Highlights



Disruptive and transformative technology

Significantly cheaper and easier to administer

Globally addressable markets

Performance better than market standard

Manufacturing & Patents secured

Initial revenues targeted for 2022




# Company Overview



## Capital Structure

ASX Code	<b>RHY</b>
<b>Share Price</b> (at 4 April 2022)	<b>\$1.76</b>
Shares on Issue	214.1 M
Unlisted Options	16.8 M
<b>Market Capitalisation</b>	<b>\$376.8 M</b>
Cash in bank (28 February 2022)	\$10.8M
Top 20 Shareholders	46%

## Share Price Chart




## Board and Management

Otto Buttula	Glenn Gilbert	Trevor Lockett	Lou Panaccio	Eduardo Vom	Rachel David
Chairman	CEO & Managing Director	Executive-Director	Non-Executive Director	Non-Executive Director	Non-Executive Director
<ul style="list-style-type: none"> <li>Extensive financial, investment and biotech experience.</li> <li>Co-Founder and CEO of IWL (ASX: IWL); Founder / former CEO of Investors Mutual.</li> <li>Formerly a Director of Imugene (ASX: IMU) and Chairman of Investorfirst, now HUB (ASX: HUB).</li> <li>Chairman of HITIQ (ASX: HIQ), Non-Executive Director of Oncosil Medical (ASX: OSL).</li> </ul>	<ul style="list-style-type: none"> <li>Former Head of Global Sales, Marketing and BD at Medical Developments Int. (ASX: MVP).</li> <li>Various leadership positions at CSL (ASX: CSL).</li> <li>Strong Legal, IP &amp; Operational management.</li> <li>Broad international business experience.</li> </ul>	<ul style="list-style-type: none"> <li>Former Theme Leader Colorectal Cancer and Gut Health CSIRO.</li> <li>Leader – Personalised Health Group CSIRO.</li> <li>Inventor on seven commercially-licensed patent families.</li> </ul>	<ul style="list-style-type: none"> <li>Chairman Avita Medical (ASX: AVH).</li> <li>Director Sonic Healthcare (ASX: SHL).</li> <li>Chairman NeuralDX.</li> <li>Non-executive Director, Adherium (ASX: ADR).</li> <li>Non-executive Director Unison Housing.</li> <li>Former CEO Melb Pathology &amp; Monash IVF.</li> </ul>	<ul style="list-style-type: none"> <li>Co-Founder &amp; Executive Director Planet Innovation.</li> <li>Director Atmo Biosciences.</li> <li>Former VP Innovation, Genetic Technologies.</li> <li>Various senior leadership positions Vision BioSystems.</li> </ul>	<ul style="list-style-type: none"> <li>Currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA).</li> <li>Senior Director Government Affairs, Policy and Market Access for Johnson &amp; Johnson.</li> <li>Various senior roles with McKinsey, CSL and Pfizer (formally Wyeth).</li> </ul>

# Market Opportunity / Addressable Market



US\$38 billion addressable screening value in priority markets<sup>1</sup>



## Colorectal Cancer Screening Market Population

Number of people over 50 years of age eligible for screening

Country	Screening participation	Addressable population
United States	63%	94 million
Europe	38%	231 million
China	19%	397 million
Japan	38%	42 million
Australia	41%	7 million
Total		771 million people

**Potential to reach ~1 billion people**  
when the screening age is lowered to 45 years old


<sup>1</sup> Based on 2021 data calculated as Eligible Screening Population (771 million) x Example Test Cost (US\$50). RHY revenue may vary.




# Australia – Growth of CRC in younger age groups




25 – 29 years old




30 – 34 years old




35 – 39 years old



40 – 44 years old



45 – 49 years old



Colorectal Cancer is the #1 cause of death in 25-34 year olds.


Top 2 cause of cancer related deaths below the age of 50.

Source: Australian Institute of Health and Welfare (AIHW). Cancer data in Australia - Cancer rankings data visualisation. <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-rankings-data-visualisation> [rhythmbio.com](https://rhythmbio.com)

# ColoSTAT® Performance



“83% of unscreened participants prefer a blood test over a faecal test”<sup>1</sup>



- **Highly accurate**  
ColoSTAT® was shown to be **35% more accurate** at detecting colorectal cancer than the current market standard Faecal Immunochemical Test (FIT).<sup>2</sup>  
  
ColoSTAT® was shown to be **more accurate** at detecting advanced adenomas than the current market standard Faecal Immunochemical Test (FIT).<sup>2</sup>
- **Low Cost and Simple**  
Protein biomarker led delivers a cost-efficient simple blood test that is suited to global mass market screening programs.
- **Detects Cancer**  
Disruptive technology that detects the presence of cancer in the blood whereas current FIT based testing regimes only detects the presence of blood in a stool sample.
- **Preferred**  
A blood test is preferred as a more acceptable way to participate in testing.

<sup>1</sup> 9. Osborne, J., Wilson, C., Moore, V., Gregory, T., Flight, I. and Young, G. (2012) Sample preference for colorectal cancer screening tests: Blood or stool?. Open Journal of Preventive Medicine, 2, 326-331. doi: 10.4236/ojpm.2012.23047.

<sup>2</sup> Internal company data for Study 7.

# Clinical Trial (Study 7) – Performance In A Clinical Setting



## PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED:

- Performance of ColoSTAT® for detection of CRC relative to colonoscopy (**Sensitivity** and **Specificity**).

### Key Steps (not exhaustive list):

- ✓ Complete patient recruitment. **Done.**
- ✓ Database locked at trial sites. **Done.**
- ✓ Testing of blood samples at Sonic Clinical Trials. **Done.**
- ✓ Statistical analysis of results. **Done.**
- Close final clinical trial site. **Underway.**
- Final clinical study report completion. **Underway.**
- Collation of data and study results / report in ColoSTAT® technical file. **Underway.**
- Submit technical file and other associated documentation to Therapeutic Goods Administration (TGA). **On track for 1HCY'22.**

### ColoSTAT® Clinical Trial confirmed:

- ✓ Performance translates to a clinical setting.
- ✓ Performance successfully met primary endpoint.
- ✓ Performance successfully met secondary endpoints.
- ✓ Supports TGA regulatory submission.

### TGA submission process requires two key filings:

- Manufacturers Evidence documentation. **Submitted and accepted**; and
- Application for an Australian Register of Therapeutic Goods (ARTG) listing. **Underway.**

# Platform Technology Expansion



- The expansion program is expected to be significantly shortened, leveraging the Company's lead biomarker which exhibits **pan-cancerous** properties;
- A platform expansion program identified a number of additional cancer target markets that have formed a new Research and Development program designed to follow a similar development pathway to ColoSTAT®;
- The initial five additional cancers to be targeted include:
  - ✓ Breast;
  - ✓ Cervical;
  - ✓ Lung;
  - ✓ Gastric; and
  - ✓ Pancreatic.
- Expedited program commenced, significant upside potential.



# Future Catalysts



- ✓ Clinical Trial (Study 7) completion and clinical study report completion;
- ✓ Technical file complete for ARTG listing for TGA submission and approval;
- ✓ Identify and progress partnering / commercialisation deals (Domestic and International);
- ✓ International country submissions / registration updates;
- ✓ Advance platform technology expansion program (progress updates); and
- ✓ Target first revenues late CY'22.



**Glenn Gilbert**  
**CEO and Managing Director, Rhythm Biosciences**  
**glenn.gilbert@rhythmbio.com**  
**+61 3 8256 2880**

[www.rhythmbio.com](http://www.rhythmbio.com)

